CANY
XBIT icon

Caxton Associates (New York)’s XBiotech XBIT Stock Holding History

Caxton Associates (New York)’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,309
Closed -$89K – 763
2022
Q1 		$89K Hold
10,309
– – 0.01% 481
2021
Q4 		$115K Hold
10,309
– – 0.01% 520
2021
Q3 		$134K Hold
10,309
– – 0.01% 418
2021
Q2 		$171K Hold
10,309
– – 0.02% 430
2021
Q1 		$177K Buy
+10,309
New +$192K 0.02% 380
2020
Q3 		– Sell
-28,765
Closed -$394K – 529
2020
Q2 		$394K Buy
+28,765
New +$404K 0.03% 184
2020
Q1 		– Sell
-14,005
Closed -$261K – 609
2019
Q4 		$261K Buy
+14,005
New +$180K 0.04% 306

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caxton Associates (New York)'s XBIT Position: Q2 2022 in Review

Caxton Associates (New York) sold out of XBiotech (XBIT) in Q2 2022, closing a stake of 10,309 shares — an estimated $89K sold.

Caxton Associates (New York) first reported a position in XBIT in Q4 2019 and held it in 7 quarters. The position peaked at $394K in Q2 2020. 56 funds tracked by Wall St. Rank hold XBIT as of Q2 2022.

  • Caxton Associates (New York) reported no remaining XBiotech position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 10,309 XBiotech shares in Q2 2022, an estimated $89K.
  • Caxton Associates (New York) first reported a position in XBiotech in Q4 2019 and held it in 7 quarters.
  • Caxton Associates (New York)'s XBiotech position peaked at $394K in Q2 2020.
  • 56 funds tracked by Wall St. Rank held XBiotech as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.